We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,481 hedge funds and large institutions have $102B invested in Bristol-Myers Squibb in 2023 Q2 according to their latest regulatory filings, with 126 funds opening new positions, 947 increasing their positions, 1,065 reducing their positions, and 163 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $1.43B | Put options by funds: $995M

0.44% less ownership

Funds ownership: 76.44%76% (-0.44%)

2% less funds holding

Funds holding: 2,5412,481 (-60)

8% less capital invested

Capital invested by funds: $111B → $102B (-$8.64B)

11% less repeat investments, than reductions

Existing positions increased: 947 | Existing positions reduced: 1,065

23% less first-time investments, than exits

New positions opened: 126 | Existing positions closed: 163

35% less funds holding in top 10

Funds holding in top 10: 6844 (-24)

Holders
2,481
Holders Change
-60
Holders Change %
-2.36%
% of All Funds
38.95%
Holding in Top 10
44
Holding in Top 10 Change
-24
Holding in Top 10 Change %
-35.29%
% of All Funds
0.69%
New
126
Increased
947
Reduced
1,065
Closed
163
Calls
$1.43B
Puts
$995M
Net Calls
+$431M
Net Calls Change
-$137M
Name Holding Trade Value Shares
Change
Change in
Stake
CS
1326
Comerica Securities
Michigan
$1.03M -$130K -1,943 -11%
MAM
1327
Mystic Asset Management
Rhode Island
$1.03M -$23.5K -350 -2%
DF
1328
Donoghue Forlines
Massachusetts
$1.02M +$218K +3,256 +26%
PMG
1329
ProVise Management Group
Florida
$1.02M -$999K -14,902 -48%
FFG
1330
Fortem Financial Group
California
$1.02M +$93.3K +1,392 +10%
SCM
1331
Schnieders Capital Management
California
$1.02M +$4.09K +61 +0.4%
FA
1332
Fountainhead AM
New Jersey
$1.01M -$45.2K -674 -4%
VCAM
1333
Van Cleef Asset Management
Ohio
$1.01M -$119K -1,777 -10%
KF
1334
Krilogy Financial
Missouri
$1.01M -$872K -13,004 -45%
STA
1335
Summit Trail Advisors
New York
$1.01M +$340K +5,064 +47%
AI
1336
Accredited Investors
Minnesota
$1M +$4.22K +63 +0.4%
CPIG
1337
Chicago Partners Investment Group
Illinois
$1M +$349K +5,209 +47%
CIM
1338
CIM Investment Management
Pennsylvania
$1M +$2.08K +31 +0.2%
ECM
1339
Estabrook Capital Management
New York
$1M -$26.8K -400 -2%
PCM
1340
Perkins Capital Management
Minnesota
$1M
SFG
1341
Sovereign Financial Group
Connecticut
$994K +$61.4K +916 +6%
Fayez Sarofim & Co
1342
Fayez Sarofim & Co
Texas
$993K +$85.4K +1,273 +9%
BFM
1343
Boston Financial Management
Massachusetts
$993K +$88.4K +1,319 +9%
CBOR
1344
Community Bank of Raymore
Missouri
$992K -$4.69K -70 -0.4%
BFWA
1345
Benchmark Financial Wealth Advisors
Florida
$988K +$36.3K +542 +4%
KA
1346
Kovack Advisors
Florida
$988K +$36.6K +546 +4%
3IP
1347
3Chopt Investment Partners
Virginia
$986K +$240K +3,584 +30%
LWM
1348
Laidlaw Wealth Management
New York
$985K -$7.04K -105 -0.7%
AW
1349
Alaethes Wealth
Nevada
$985K +$40.2K +600 +4%
RIA
1350
Richwood Investment Advisors
Ohio
$984K -$3.29K -49 -0.3%

BMY Hedge Fund Activity: Q2 2023 in Review

2,481 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2023, worth a combined $102B — down 7.8% from $111B a quarter earlier.

Sellers outnumbered buyers: 163 funds closed out of BMY and 126 opened new positions — a net loss of 37 holders — while 1,065 trimmed existing stakes and 947 added.

The largest buyer was Capital International Investors, adding an estimated $528M. The largest seller was Bank of America, cutting an estimated $634M.

  • 2,481 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2023, down from 2,541 in Q1 2023.
  • Funds reported $102B of Bristol-Myers Squibb stock for Q2 2023, down 7.8% quarter-over-quarter.
  • 126 funds opened new Bristol-Myers Squibb positions in Q2 2023 and 163 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q2 2023 was Capital International Investors, an estimated $528M added.
  • The largest Bristol-Myers Squibb seller in Q2 2023 was Bank of America, an estimated $634M sold.

Based on aggregated 13F filings for Q2 2023.